Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

This study is testing a combination of two cancer drugs — fruquintinib (a targeted therapy) and sintilimab (an immunotherapy) — in women with advanced or recurrent endometrial (uterine) cancer that has already been treated with chemotherapy. **You may be eligible if...** - You are between 18 and 75 years old with a BMI of at least 18.5 - You have confirmed advanced or recurrent endometrial cancer with measurable disease - You have already received at least one prior platinum-based chemotherapy regimen - Your overall health status is rated 0–1 on standard performance scales - Your major organ functions (heart, liver, kidneys) are within acceptable ranges **You may NOT be eligible if...** - You have uncontrolled high blood pressure, active bleeding, or recent blood clots - You have received prior treatment with fruquintinib, sintilimab, or similar drugs - You are pregnant or breastfeeding - You have an active autoimmune disease requiring treatment - You have untreated brain metastases - You have serious heart conditions or unhealed wounds Talk to your doctor to see if this trial is right for you.